Your current dose is already working well
Slow dose escalation This is the single most effective strategy for reducing side effects with both medications
Recent studies have documented that GLP-1R engagement in the portal circulation is reduced under high-fat dietfeeding conditions (68), suggesting together with our data that multiple mechanisms converge to control GLP-1 action in the hepatic portal circulation, which may contribute to glucose dysregulation in mice upon high-fat feeding
Recent Timeline Updates August 2023: The first major GLP-1 lawsuit was filed, opening the door for thousands of similar claims against Mounjaro and other weight loss drugs
The CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials showed that canagliflozin, dapagliflozin, and empagliflozin, respectively, are associated with a reduction in the composite outcome of death from renal or CV causes, end-stage renal disease, or worsening of serum creatinine or eGFR [[68-70]